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Abstract 
PD-L1, also known as B7-H1, is a type I transmembrane protein, which is expressed in different kinds of 
tumor cells. It is correlated with poor clinical outcome of patients with various types of tumors. PD-L1 can 
regulate tumor microenvironment or tumor related immune response through suppressing T cell or NK cell 
mediated immune response. PD-L1 expression is regulated by various cytokines, such as LPS, GM-CSF, IL-4, 
TGF-β, TNF-α. PD-1 and PD-L1 are the members of B7 and CD28 superfamily, respectively. The B7/CD28 
interaction plays a central role in immune tolerance. PD-L1 can bind to PD-1, which leads to the 
suppression of lymphocyte activation and apoptosis of lymphocytes. Anti-PD-L1 therapy is one of the 
immunotherapies to treat cancer (especially solid tumor). PD-L1 expression may be associated with efficacy 
of anti PD-1/PD-L1 therapy. In this review, we will focus on the regulation mechanism of PD-L1 expression, 
and describe the role of PD-1/PD-L1 binding on the anti-PD-1/PD-L1 therapy. 
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Introduction 
Cancer is the first leading cause of death in China and second leading cause of death in United States in 
recent years [1, 2]. Although, the cancer death rates have declined over 2 decades, the death rates caused 
by cancers of uterine corpus and liver are still increasing. It is estimated that by 2030 about 13–17 million 
people will die from cancer [3]. Cancer is a major public health issue, and the search for advanced 
detection methods and novel treatments are important. Cancer treatments include various types of 
therapies, such as surgery, radiation, chemotherapy, biological therapy and targeted therapy [4-8]. Among 
these therapies, immunotherapy for cancer has now become a new standard strategy to treat cancer. With 
the approval of rituximab and trastuzumab, immunotherapy the field of cancer therapy changed 
considerably [9]. Over recent decades, immunotherapy has been used for solid and hematological 
malignances treatment [10]. There are several types of immunotherapy, including vaccines, monoclonal 
antibodies, T cell therapy, oncolytic virus therapy, non-specific immunotherapies [11-15]. As one of 
approaches of immunotherapy, antibody-based cancer therapy employs monoclonal antibodies targeting 
receptor tyrosine kinase (RTKs), immune checkpoint inhibitor, or other membrane antigens. Antibodies 
targeting RTKs (such as human epidermal growth factor receptor 2 (HER2) and extracellular signal 
regulated kinase (ERK)) are often limited by resistance. For example, colorectal cancer patients are 
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resistant to cetuximab and panitumumab (anti- epidermal growth factor receptor (EGFR) antibodies) when 
the tumor has a mutated Ras-protein [16, 17]. Bispecific antibodies (bsAb) and Homo-combinations of 
antibodies targeting RTKs are employed to improve sensitivity of patients to antibodies[18]. Immune 
checkpoint inhibitor, such as anti-programmed cell death protein 1 (PD-1) antibody, anti-programmed 
death ligand 1 (PD-L1) antibody and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, 
can enhance the ability of cytotoxic T cells to recognize tumor without limitation by resistance [19]. PD-L1 
is known as B7 homolog 1 (B7-H1) or cluster of differentiation (CD274) and is recognized as a cell surface 
protein belonging to B7 superfamily. Many studies have reported that PD-L1 can suppress T lymphocyte 
activation through interacting with some PD-L1 receptor, such as PD-1. 
PD-L1 directed therapy of cancer 
Many studies showed that PD-L1 expression is present in various kinds of tumors, which suggested that 
PD-L1 may be closely related with cancer. Liu et al. demonstrated that PD-L1 expression was found in 
multiple myeloma plasma cells, but not in cells which were isolated from monoclonal gammopathy or 
healthy donors [20]. PD-L1 expression has not only been found on glial tumor cells, but also on various 
brain metastases [21, 22]. 66 % of freshly isolated Head and neck squamous cell carcinoma (HNSCC) 
showed constitutive expression of PD-L1 [23]. Except for cancers mentioned above, upregulation of PD-L1 
has also been found in other common cancers, such as melanoma, ovarian cancer, lung cancer, urothelial 
carcinoma, esophageal cancer, cervical cancer, pancreatic cancer and Wilms tumor [24-31].  
Recent clinical data showed that increased expression of PD-L1 was closely related with a poor 
prognosis in chronic hepatitis B virus (HBV) infected hepatocellular carcinoma patients [32]. In breast 
cancers it was shown that in this disease a higher expression of PD-L1 had a strong link with several 
characteristics, such as tumor size, American Joint Committee on Cancer (AJCC) primary tumor 
classification, tumor grade, lymph node status, and high Ki-67 expression [33]. Meanwhile, PD-L1 was also 
shown to be related to poor prognosis in human breast cancer [33]. Upregulation of PD-L1 was closely 
related with late stage clinical development and decreased rate of disease-free survival [34]. Sarah et al. 
reported that PD-L1 was expressed in tumor cells of patients with Epstein-Barr Virus (EBV) infected gastric 
cancer (GC), but not in other GC cancer cells [35].  
Besides, preclinical experiments also showed an effect of PD-L1 on tumor treatment. In an acute 
myeloid leukemia (AML) model, blockade of PD-L1 by antibodies enhanced immune response against 
leukemia cells (C1498.GFP cells) in C57BL/6 mice [36]. Meanwhile, CD8+ T cell receiving anti-PD-L1 
antibody was shown to increase in livers from C57BL/6 mice compared to control without treatment with 
antibodies [36]. Iwai et al. showed that in vitro P815 cells transfected with pApuroXS-PD-L1 stably 
expressed PD-L1, and was susceptible to T cell antigen receptor (TCR)-mediated lysis induced by Cytotoxic 
T cells [37]. Most importantly, tumorigenesis and invasiveness of these tumor cells was enhanced 
compared to parental cells which didn’t express PD-L1 [37]. The promoting effect of PD-L1 on cancer was 
also shown by suppression of anti-PD-L1 antibody on the growth of myeloma cells [37]. 
PD-L1expression in immune diseases 
As a target of immune checkpoint inhibitor, PD-L1 is not only associated with anti-cancer treatment, but 
also with other immune diseases. PD-L1 has a strong link with autoimmune disease. In non-obese diabetic 
(NOD) prediabetic murine model, PD-L1 expression was significantly upregulated on infiltrating 
mononuclear cells in the islet [38]. Mohammed et al. also reported that expression of PD-L1 was found in 
the inflamed islets of NOD mice, suggesting a regulatory role of PD-L1 on the progression of autoimmune 
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diabetes [39]. PD-L1 has been reported to contribute to etiopathogenetic of autoimmune diseases in 
mouse models. Mohammed et al. reported that blockade of PD-L1 by monoclonal antibodies (mAbs) 
against PD-L1 led to diabetes in female NOD mice [39]. The NOD mouse model is useful for studying 
diabetes caused by autoimmune process [40]. Blockade of PD-1/PD-L1 interaction didn’t induce diabetes in 
NOR mice, showing the specific islet cell toxicity by mAbs treatment [39]. Bing et al. reported that in 
BALB/c mice, blockade of PD-L1 remarkably increased incidence of experimental autoimmune 
encephalomyelitis (EAE) in the presence of myelin oligodendrocyte glycoprotein (MOG) peptide 35–55 
[41]. Furthermore, in myelin proteolipid protein (PLP) peptide 139–151 immunized B10.S mice, blockade of 
PD-L1 also significantly enhanced severity of EAE [41]. PD-L1 deficiency mice were completely susceptible 
to EAE after E2 (known as 17β-estradiol, an estrogen) treatment [42]. This study also reported that the 
protective effect against EAE mediated by E2 was significantly reduced in recipient mice transfected with 
PD-L1−/− B-cell [42]. Therefore PD-L1 in B cells may be crucial for the protective effect of estrogen against 
EAE. Enhanced expression of PD-L1 was present on ductal and acinar epithelial cells in the salivary glands of 
patients with Sjogren’s syndrome [43]. Increased expression of PD-L1 has also been found on T cells, B cells 
as well as monocytes of patients with Systemic Lupus Erythematosus (SLE), implying that PD-L1 might be 
correlated with SLE disease [44]. The expression of PD-L1 increased on mononuclear cells in the lamina 
propria of inflammatory bowel disease (IBD) patients, as well as on mononuclear cells in the lamina propria 
in experimental colitic mice [45].  
PD-L1 in virus associated disease 
Besides, PD-L1 is also associated with chronic viral infection and chronic inflammatory diseases. 
Upregulated expression of PD-L1 was found in livers of patients infected with HBV compared with healthy 
donors [46]. Previous studies showed that most of Merkel Cell Carcinoma (MCC) were linked to Merkel Cell 
Polyomavirus (MCPyV) infection [47]. Enhanced expression of PD-L1 was found in MCPyV infected MCC 
cells compared to MCPyV-negative MCC cells [48]. It was reported that Interferon (IFN)-γ had an effect on 
increasing the number of CD8+ cytotoxic T lymphocytes (CTLs) when infected by the virus [49]. Blockade of 
PD-L1 enhanced the ability of CD8+ CTLs to produce IFN-γ through an increase in the number of IFN-γ-
producing HBV-specific CTLs [50]. Daniel et al. reported that in Lymphocytic Choriomeningitis virus (LCMV) 
infected mice blockade of PD-L1 and PD-1 interaction restored the ability of exhausted CD8 T cell to kill 
infected cells [51]. The PD-L1/PD-1 pathway has also been found to mediate the function of virus-specific 
exhausted CD8+ T cell in human immunodeficiency virus (HIV) infected patients in several studies [51]. Dai 
et al. showed that blockade of interaction of PD-1/PD-L1 by anti-PD-L1 restored immune response 
generated by CD8+ T cell after being infected by HIV [52]. Anti-PD-L1 antibody also enhanced proliferation 
and cytokine production of hepatitis C virus (HCV)-specific CD8 cells during chronic HCV infection in the 
study reported by Simona et al. [53]. The result of these studies suggested that PD-L1 can inhibit the 
immune response during chronic viral infection [54]. PD-L1 was involved in intestinal mucosal 
inflammation, such as ulcerative colitis. In severe combined immune-deficient (SCID) mice, which were 
reconstituted with CD45RBhigh CD4+ T cells, blockade of PD-L1 by mAbs against B7-H1 suppressed wasting 
disease with colitis [45]. 
Role of PD-L1 in efficacy of treatment 
Pre-clinical data showed that the anticancer effect of anti-PD-L1 antibody is different kinds of cancer 
cells. Meanwhile, clinical activity of anti-PD-L1 antibodies has been observed in various malignancies, such 
as melanoma, non-small cell lung cancer, squamous head and neck cancer, microsatellite-unstable 
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colorectal cancer, and other types of cancers [55-58]. A predictive role of PD-L1 expression and TIL (tumor 
infiltrating lymphocytes) has been found in lung cancer patients receiving anti-PD-1/PD-L1 immunotherapy 
and could be used to improve clinical interpretations [59]. However, PD-L1 expression can be constitutive 
and inducible. Induced PD-L1 upregulation is regulated by various other cytokines, such as IFN, Tumor 
necrosis factor (TNF)-α and Toll-like receptor (TLR) etc. [60]. Most importantly, PD-L1 upregulation can also 
improve survival of mice with lung tumor, which received anti-PD-L1 treatment [61]. This review will 
discuss the basic structure of PD-L1, which is important for PD-L1 regulation and therapy. Besides, this 
review will also discuss regulation and signaling pathway of PD-L1, which can influence anti-PD-L1 
immunotherapy.  
Structure of PD-L1 
PD-L1 was found by searching the expressed sequence tag database (generated from dendritic cells and 
activated macrophages) for molecules which contain homology to B7-1 and B7-2 [62]. PD-L1 is encoded by 
the CD274 gene, which is situated on mouse chromosome 19 and human chromosome 9 at a band p24. 
PD-L1 is a 40kDa protein containing 290 amino acid. Human PD-L1 shares 70 % homology in amino acids 
with mouse PD-L1 [63]. Mazanet et al. reported that the promoter region of CD274 gene consisted several 
elements responded to IFN-γ, which was necessary for upregulation of PD-L1 expression mediated by IFN-γ 
[64]. PD-L1 exerts a role as a type I transmembrane protein and contains four domains [56]. They are Ig 
(immunoglobulin) V-like domain, Ig C-like domain, and hydrophobic transmembrane domain, as well as 
cytoplasmic domains, encoded by single exon sequences [62]. The schematic diagram and structure of PD-
L1 is shown in Figure 1. The Ig V-like domain and Ig C-like domain are two anti-parallel β sandwich 
immunoglobulin superfamily (Ig SF) domains, which are related to domains of immunoglobulins [65, 66]. 
The Ig V-like domain is formed by BED and AGFCC’C’’ β sheets, and necessary for interaction of PD-L1 and 
B7-1 in murine [67]. What’s more, the PD-L1:PD-1 binding interface is also on its Ig V-like domain. The Ig C 
domain of PD-L1 has C1-set domains with β-strands forming ABED and CFG sheets [66]. The cytoplasmic 
domain which is encoded by the last exon is about 30 amino acids, and highly conserved in all species 
reported [23]. While a potential site of PD-L1 which could be phosphorylated by Protein Kinase C (PKC) is 
on its intracellular domain [23]. 
Regulation of PD-L1 
    PD-L1 expression is present on antigen-presenting cells (APCs), such as human monocytes, as well as 
activated human and murine dendritic cells. Moreover, PD-L1 is also expressed in nonlymphoid tissues 
such as heart and lung, thymus, kidney. PD-L1 is easily induced by pro-inflammatory cytokines on different 
kinds of cells, which is shown in Figure 2. 
PD-L1 can be induced by IFN-γ and TLR ligands in MM plasma cells [20]. This study revealed that 
blockade of mitogen-activated protein kinase (MAPK)/ERK pathway and inhibition of signal transducer and 
activator of transcription 1（STAT1）suppressed the enhanced expression of PD-L1 induced by IFN-γ [20]. 
Meanwhile, inhibition of the Myeloid differentiation primary response gene 88（MyD88）and TNF 
receptor-associated factor 6（TRAF6）has been reported to inhibit PD-L1 expression either induced by 
TLR ligands or by IFN-γ [20]. In human lung cancer cells interferon regulatory factor-1 (IRF-1) was necessary 
for induction of PD-L1 expression mediated by IFN-γ in STAT1-manner [68]. Besides, a recent study also 
showed that enhanced expression of PD-L1 induced by TLR also was dependent on IL-, IL-10 and STAT3 in 
APCs [69]. In addition, IFN-α has also been reported to induce upregulated mRNA expression and protein 
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expression of PD-L1 on microvascular endothelial cells (ECs) [70]. Moreover the enhanced expression of 
PD-L1 protein and mRNA was induced by IFN-β on monocytes and mature dendritic cells of healthy donors 
and multiple sclerosis (MS) patients [71].  
 
Figure 1. Schematic diagram and structure of PD-L1 protein. A. Schematic diagram of PD-L1 protein. SP: Signal 
peptide; ECD: Extracellular Domain; TM: Transmembrane Domain; ICD; Intracellular domain. B. Structure of 
PD-L1 protein. This structure shows two main anti-parallel β sandwich immunoglobulin superfamily (Ig SF) 
domains of PD=L1 protein. 
Inflammatory macrophages upregulate expression of PD-L1, which was also induced by 
lipopolysaccharide (LPS) [72]. Enhanced expression of PD-L1 was present on immature dendritic cells (iDCs) 
after being treated with granulocyte-macrophage colony-stimulating factor (GM-CSF) [73]. Ou et al. 
reported that in SLE monocytes opposing actions of TNF-α and Transforming growth factor (TGF)-β 
regulated the expression of PD-L1 [74]. PD-L1 expression could be revived by exogenous TNF-α on lupus 
monocytes [74]. TGF-β has shown to inhibit PD-L1 expression on monocytes [74]. Induction of PD-L1 
expression is also associated with Janus kinase (JAK)/STAT signaling and Activator protein 1 (AP1) activity 
[75]. Michael et al. showed that in classical Hodgkin lymphoma Reed–Sternberg cells constitutive activation 
of AP-1 resulted in the binding of AP-1 components to enhancer of CD274 gene, which enhanced the 
activity of PD-L1 promoter [75]. The induction of PD-L1 expression by JAK2 was also observed in this study, 
which was associated with JAK/STAT-dependent promoter in CD274 gene [75]. Besides, the increase of PD-
L1 expression protein was induced by inhibition of phosphatase and tensin homolog (PTEN) in glioma 
cancer and colorectal cancer [22]. Recent studies reported that PD-L1 expression was inhibited by p53 
through regulating miR-34a and miR-200 [76, 77]. 
The IL family also was indicated to be important for induction of PD-L1 expression. For instance, IL-27 
enhanced the expression of CD274 gene which is dependent on STAT1 on naïve T cells [78]. Further study 
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showed that PD-L1 expression was increased which was mediated by IL-4 in nuclear factor-kappa B (NF-κB) 
p50–/– p65+/– dendritic cell (DC) [38]. 
The PD-L1 expression was not only induced by multiple pro-inflammatory molecules, but also 
influenced by T cells. For example, enhanced expression of PD-L1 induced by Type 1 T helper (Th1) cells 
was also found on different macrophages [72]. Activation of human T cells by anti-CD3 and anti-CD28 may 
lead to increased expression of PD-L1 mRNA [79]. 
 
 
Figure 2. PD-L1 expression is regulated by several cytokines. A. Upregulation of PD-L1 is induced by various 
pro-inflammatory molecules. PD-L1 could be induced by IFN-γ and TLR ligands via regulation of downstream 
adaptor proteins of the TLR signaling pathway. IFN-γ also induced PD-L1 expression through JAK-STAT1 
signaling pathway. Except that, some other cytokines, like GM-CSF, TNF-alpha, IL , can increase PD-L1 
expression. B. Inhibition of PD-L1 expression is mediated by p53, PTEN and TGF-β. 
PD-L1/PD-1 signaling pathway  
Several studies reported that PD-L1 can interact with PD-1, and this interaction delivered an inhibitory 
signals to regulate immune tolerance and immunopathology [80]. Most importantly, PD-L1/PD-1 signaling 
may exert its inhibitory effect on immune response through signaling pathway mediated by various types 
of cytokines, such as SHP-1, TCR, Phosphoinositide 3-kinase (PI3K). Figure 3 shows PD-L1/PD-1 signaling 
pathway regulating T cell survival. 
The effector T cells interaction of PD-L1 and PD-1 blocked TCR signal transduction, leading to inhibition 
of T cell cytotoxic activity [81].  The Src homology region 2 domain containing phosphatase-1 (SHP1) could 
regulate activation of CD8+ T cell and inhibition of SHP-1 by sodium stibogluconate enhanced the function 
of T cells [82]. The cytoplasmic domain of PD-1 consists of two motifs, including the tyrosine-based 
inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) [83]. The PD-1 and PD-L1 
interaction can phosphorylate a tyrosine in the ITSM motif of PD-1, and then recruit the SHP-1 and SHP2 to 
the ITSM motif [84]. After recruiting, this signaling pathway can inhibit stop signals, and block the 
interaction of T cells and dendritic cells [85]. Finally, blockade of the TCR signal transduction caused 
inhibition of the PI3K/AKT (AKT is known as Protein kinase B) and MAPK signaling [86]. Most importantly, 
inhibition of PI3K activation suppresses the expression of B cell lymphoma extra-large (Bcl-xL) and 
activation of AKT, which furtherly leads to increased apoptosis of T cells [12]. 
PD-L1 not only inhibits function of activated T cell via inhibition of PI3K/AKT pathway and Ras/MEK/ERK 
pathway, but also through inhibition of transcription factors necessary for T cell survival. PD-L1 and PD-1 
interaction was reported to inhibit expression of GATA-3 and T-bet [87]. GATA-3 has been reported to be a 
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transcription factor which is critical for differentiation of T helper 2 (Th2) cells [21]. Meanwhile, T-bet, 
which is known as T-box transcription factor, can contribute to T-cell development [88]. 
PD-L1/PD-1 interaction is also involved in signal pathway mediated by TGF-β. Loise et al. reported that 
the function of TGF-β in induced T cell regulatory (iTreg) cell development could be reduced by the loss of 
PD-L1 [89]. This study also reported that during the conversion of iTreg cells from mature T cells, PD-L1/PD-
1 signaling reduced the phosphorylation of AKT and its downstream substrates mTOR and S6 [89].  
Barber et al. reported that in exhausted CD8+ T cell blockade of PD-L1 and PD-1 signaling pathway 
enhanced T cell ability to secrete cytokine and kill infected cells with LCMV, suggesting that the PD-L1/PD-1 
signaling pathway affected activation of downstream molecules of the T cell activation [51]. The study 
reported by Carter et al. showed that PD-L1 and PD-1 interaction inhibited IL-2 production in CD4+ and 
CD8+ T cell, which further inhibited lymphoproliferation [90]. In endothelial cells mouse anti-PD-L1 blocked 
the interaction of PD-L1 and PD-l, and stimulated IFN-γ production secreted by CD8+ T cell, resulting in T 
cell activation [91]. In Hodgkin lymphoma -infiltrating T cells, inhibition of the activation of PD-1 and PD-L1 
signaling pathway led to inhibition of SHP-2 phosphorylation and increased the production of IFN-γ [92]. In 
the liver PD-L1 and PD-1 interaction led to reduced IFN-γ production secreted by CD8+ T Lymphocytes(CLT) 
[50]. 
 
Figure 3. The PD-L1/PD-1 signaling pathway in T cells. PD-L1/PD1 signaling pathway could mediate T cell 
survival through regulation of different signal transductions. PD-1 and PD-L1 interaction leads to PD-1 
phosphorylation, and recruits SHP-1 and SHP2 to the ITSM motif of PD-1. After recruiting, this signaling 
pathway blocks the interaction of T cells. Blockade of TCR signal transduction inhibited the PI3k/Akt and 
MAPK signaling. Inhibition of PI3K activation suppressed the expression of B cell lymphoma extra-large (Bcl-xL) 
and activation of Akt, which leads to increased apoptosis of T cells. PD-L1 and PD-1 interaction also inhibits 
expression of GATA-3 and T-bet. GATA-3 is critical for differentiation of Th2 cells. T-bet contributes to T-cell 
development. 
Conclusions 
This review describes the regulation of the PD-L1/PD-1 signaling pathway. PD-L1 is a transmembrane 
protein, and inhibits the function of T cell through binding to its receptor PD-1. The interaction of PD-L1 
and PD-1 inhibits T cell activation and proliferation, which inhibits the function of T cells to produce 
cytokines and kill targeting tumor cells. Blockade of PD-L1 signaling by anti-PD-L1 antibodies not only 
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inhibits tumor growth, but also leads to etiopathogenetic of autoimmune diseases (such as diabetes). 
There are several kinds of antibodies in development against PD-L1 in cancer immunotherapy, such as 
atezolizumab, avelumab, durvalumab, BMS-936559. The safety study with BMS-936659 showed that in 
39% patient side effects such as rash, hypothyroidism, diabetes mellitus, myasthenia gravis and other 
disease occurred [93]. This makes PD-L1 an attractive target for anti-cancer therapy. However, knowledge 
on the side effects of anti-PD-L1 therapy is still limiting and, more studies are needed to get a better in the 
regulation of PD-L1 on cancer.  
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